Altamira Therapeutics Transitions from Nasdaq to OTCQB
Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (OTCQB: CYTOF), a leader in RNA delivery technology, has announced a significant transition from being listed on The Nasdaq Stock Market to the OTCQB marketplace. This change was initiated following a determination from the Nasdaq Hearings Panel to delist the Company’s common shares due to non-compliance with their listing rules regarding maintaining a minimum bid price.
Details of the Delisting
The Nasdaq ruling came as a result of the Company’s common shares failing to reach the required minimum bid price of $1.00. Despite Altamira’s previous efforts to appeal and present a compliance strategy, the Panel denied the appeal, leading the Company to move towards trading on the OTCQB.
The planned delisting from Nasdaq is set to take place, ensuring that shareholders will continue to have access to their investments under the new trading symbol “CYTOF”. This transition is designed to facilitate uninterrupted trading activity for existing shareholders without the need for any additional measures on their part.
Focus on Growth in RNA Delivery Technology
In reflecting on this transition, Thomas Meyer, Altamira’s founder and CEO, expressed optimism about the future. He emphasized that moving to the OTCQB marketplace offers the Company a robust platform that is more suited for developing firms like Altamira, particularly given its focus on RNA delivery systems that target areas beyond just the liver.
Altamira is recognized for its innovative approach, particularly with its OligoPhore™ and SemaPhore™ platforms that promise effective RNA delivery to extrahepatic tissues. This technology serves as a backbone for their current projects including AM-401 for KRAS-driven cancer and AM-411 for rheumatoid arthritis, both of which have made significant progress in preclinical development.
Prospects and Future for Altamira Therapeutics
Shifting to the OTCQB represents a strategic opportunity for Altamira to concentrate efforts on expanding its RNA delivery platforms. As the OTCQB does not impose a minimum bid price requirement, the Company can avoid undergoing any reverse stock splits, which often pose an additional challenge for publicly traded companies.
Furthermore, Altamira continues to explore partnerships and potential licensing agreements to further enhance the reach of its advanced technology. The versatile delivery system is not limited to just siRNA but is designed to accommodate other types of RNA therapies, making it appealing for collaborations with pharmaceutical and biotech firms.
Legacy Assets and Other Initiatives
In addition to its RNA-related projects, Altamira holds a 49% stake in Altamira Medica AG, which markets Bentrio®, a nasal spray targeted at allergic rhinitis. The Company is also actively pursuing options for its inner ear legacy assets, showcasing its commitment to exploring various avenues for growth and innovation.
Conclusion
Altamira Therapeutics is poised to enter this new chapter as it transitions to the OTCQB marketplace. This move reflects the Company’s resilience and dedication to pioneering solutions in RNA delivery technology. As it continues to advance its innovative platforms and explore new opportunities, Altamira aims to solidify its position in the biotechnology landscape and deliver value to its shareholders.
Frequently Asked Questions
What prompted Altamira's transition to the OTCQB?
The transition was prompted by a decision from the Nasdaq Hearings Panel to delist the Company's shares due to non-compliance with minimum bid price regulations.
How will this affect shareholders?
Shareholders will see no interruption in trading and will continue to hold their shares under the new ticker symbol “CYTOF” on the OTCQB.
What are Altamira's primary areas of focus?
Altamira focuses on developing effective RNA delivery technologies, particularly with its OligoPhore™ and SemaPhore™ platforms, which target various applications beyond the liver.
Is Altamira planning any reverse stock splits?
No, as the OTCQB does not have a minimum bid price requirement, the Company is not planning any reverse stock splits.
What legacy assets does Altamira hold?
Altamira holds a 49% stake in Altamira Medica AG, and it is actively working on initiatives related to its nasal spray for allergic rhinitis and its inner ear assets.
